The combination of DDR inhibitors and VEGF inhibitors demonstrated superior efficacy compared to standard platinum-based therapy in wild-type tumors within this study, suggesting the potential for DDR-based therapy to replace more toxic chemotherapy in early treatment and thereby enhance the quality of life for cancer patients. Here, DDR1 is linked to cancer.